Abstract
Current treatments for cocaine addiction are not effective. The development of a catalytic monoclonal antibody (mAb) provides a strategy for not only binding, but also degrading cocaine, which offers a broad-based therapy. Hapten design is the central element for programming antibody catalysis. The characteristics of the linker used in classic transition-state analogue phosphonate haptens were shown to be important for obtaining mAbs that hydrolyze the benzoate ester of cocaine.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antibodies, Catalytic / metabolism*
-
Antibodies, Catalytic / therapeutic use
-
Antibodies, Monoclonal / metabolism
-
Antibodies, Monoclonal / therapeutic use
-
Cocaine / immunology*
-
Cocaine / metabolism
-
Cocaine-Related Disorders / drug therapy
-
Drug Design
-
Haptens / chemistry
-
Hydrolysis
-
Kinetics
-
Mice
-
Organophosphonates / chemistry
-
Structure-Activity Relationship
Substances
-
Antibodies, Catalytic
-
Antibodies, Monoclonal
-
Haptens
-
Organophosphonates
-
Cocaine